151 related articles for article (PubMed ID: 6752720)
1. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.
Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ
N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720
[TBL] [Abstract][Full Text] [Related]
2. Acute leukemia after alkylating-agent therapy of ovarian cancer.
Reimer RR; Hoover R; Fraumeni JF; Young RC
N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
[TBL] [Abstract][Full Text] [Related]
3. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma.
Greene MH; Young RC; Merrill JM; DeVita VT
Cancer Res; 1983 Apr; 43(4):1891-8. PubMed ID: 6572558
[TBL] [Abstract][Full Text] [Related]
4. Acute leukemia in advanced ovarian carcinoma after treatment with alkylating agents.
Sotrel G; Jafari K; Lash AF; Stepto RC
Obstet Gynecol; 1976 Jan; 47(1):67S-71S. PubMed ID: 1061006
[TBL] [Abstract][Full Text] [Related]
5. Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
Curtis RE; Boice JD; Stovall M; Bernstein L; Greenberg RS; Flannery JT; Schwartz AG; Weyer P; Moloney WC; Hoover RN
N Engl J Med; 1992 Jun; 326(26):1745-51. PubMed ID: 1594016
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents.
Bennett JM; Moloney WC; Greene MH; Boice JD
Hematol Pathol; 1987; 1(2):99-104. PubMed ID: 3504435
[TBL] [Abstract][Full Text] [Related]
7. Acute leukaemia after alkylating-agent therapy of ovarian cancer.
Bell DR; Woods RL; Levi JA
Med J Aust; 1982 Sep; 2(5):243-4. PubMed ID: 7132879
[No Abstract] [Full Text] [Related]
8. Leukemia following chemotherapy for breast cancer.
Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
[TBL] [Abstract][Full Text] [Related]
9. Risk of leukemia after platinum-based chemotherapy for ovarian cancer.
Travis LB; Holowaty EJ; Bergfeldt K; Lynch CF; Kohler BA; Wiklund T; Curtis RE; Hall P; Andersson M; Pukkala E; Sturgeon J; Stovall M
N Engl J Med; 1999 Feb; 340(5):351-7. PubMed ID: 9929525
[TBL] [Abstract][Full Text] [Related]
10. Leukemia after treatment of ovarian cancer with alkylating agents.
Parker LM
N Engl J Med; 1983 Jun; 308(23):1422. PubMed ID: 6843637
[No Abstract] [Full Text] [Related]
11. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).
Boice JD; Greene MH; Killen JY; Ellenberg SS; Keehn RJ; McFadden E; Chen TT; Fraumeni JF
N Engl J Med; 1983 Nov; 309(18):1079-84. PubMed ID: 6353233
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
13. Leukemia following chemotherapy for ovarian cancer.
Kaldor JM; Day NE; Pettersson F; Clarke EA; Pedersen D; Mehnert W; Bell J; Høst H; Prior P; Karjalainen S
N Engl J Med; 1990 Jan; 322(1):1-6. PubMed ID: 2104664
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of secondary acute nonlymphocytic leukemias. Cytological aspects (a review).
Raposa T; Várkonyi J; Gráf F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):180-5. PubMed ID: 6208100
[TBL] [Abstract][Full Text] [Related]
15. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP
Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213
[TBL] [Abstract][Full Text] [Related]
16. Leukemia after therapy with alkylating agents for childhood cancer.
Tucker MA; Meadows AT; Boice JD; Stovall M; Oberlin O; Stone BJ; Birch J; Voûte PA; Hoover RN; Fraumeni JF
J Natl Cancer Inst; 1987 Mar; 78(3):459-64. PubMed ID: 3469460
[TBL] [Abstract][Full Text] [Related]
17. [Plasmocytoma, alkylating agents, and acute myeloid leukemia (author's transl)].
Schmalzl F; Keiser G; Kresbach E; Fritz H; Asamer H; Braunsteiner H
Dtsch Med Wochenschr; 1975 Sep; 100(39):1961-7. PubMed ID: 1057506
[TBL] [Abstract][Full Text] [Related]
18. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
19. Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.
Lerner HJ
Cancer Treat Rep; 1978 Aug; 62(8):1135-8. PubMed ID: 278642
[TBL] [Abstract][Full Text] [Related]
20. Melphalan may be a more potent leukemogen than cyclophosphamide.
Greene MH; Harris EL; Gershenson DM; Malkasian GD; Melton LJ; Dembo AJ; Bennett JM; Moloney WC; Boice JD
Ann Intern Med; 1986 Sep; 105(3):360-7. PubMed ID: 3740675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
